🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million instances annually. Particularly high rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval represents a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

According to data published in a major medical journal, the new drug cured more than 90% of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in numerous regions with limited resources.

Clinicians on the front lines have expressed positive views. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is considered essential to lessen the impact of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.